Home  »  Company  »  Cipla Ltd.  »  Quotes  »  Company History
Enter the first few characters of Company and click 'Go'

Cipla Ltd. Company History and Annual Growth Details


- The Company was Incorporated at Mumbai.


- The Company acquired a plot of land from MIDC at Patalganga in Kulaba
district of Maharashtra State about 55 kms. from Mumbai.

- 18,773 Bonus equity shares issued in proportion 1:1.


- The name of the Company was changed from The Chemical Industrial &
Pharmaceutical Laboratories Ltd., to the present one with effect from
20th July.


- 37,546 Bonus equity shares issued in proportion 1:1 in January 1986.


- During August, the Company obtained the consent of the Controller of
Capital Issues to issue 3,00,000-15% secured non-convertible redeemable
debentures of Rs 100 each aggregating to Rs 300 lakhs by private
placement. The entire issue was subscribed by public financial
institutions. They are redeemable at a premium of 5% during 1993-94.


- The Company launched several new products viz., Asthalin and Beclate
Rotahalers/Rotacaps-dry powder inhalation devices for asthma, presolar
capsules - the first synergistic combination of a beta blocker and a
sustained release calcium channel blocker for hypertension, Restyl
tablets - the first anxiolytic-cum-anti depressant, Theo-Asthalin SR
tablets - the first sustained release combination of two widely used
bronchodilators, bromolin dry syrup and bromolin-250 capsules -
antibiotic-cum-mucolytic agents, dilgard tablets - a new calcium
channel blocker for angina, ibugesic plus suspension - a non steroidal
anti inflammatory and anti-pyretic analgesic for paediatric use.

- 75,092 Bonus equity shares issued in proportion 1:1.


- The latest drugs introduced during the year were (i) Ciplox tablets
(250 & 500 mg.) and infusion (50 and 100 ml.), a broad spectrum
fluoroquinolone antibacterial for severe infections, (ii) cefadur
capsules (250 & 500 mg.) and syrup (30 ml.), a cephalosporin
antibiotic, (iii) Ulcimax tablets (20 & 40 mg.), a long-acting H2
antogonist for peptic ulcers and (iv) theoped syrup, a paediatric
bronchodilator. Sales in the Company's 'PROTEC' division exceeded Rs
5.50 crores for the second year of its operations.


- The Company launched several new products viz., Aerocort inhaler, an
anti-inflammatory bronchodilator, Norflox eye/ear drops - a broad
spectrum fluoroquinolone antibacterial, Pirox Gel - the first topical
piroxicam formulation in the country, Cofenac tablets - an
anti-infammatory analgesic, Kinetal 400 tablets - a multi-functional
drug for vascular insufficiency, Novaclox Ped tablets - a dispensible
combination antibiotics, Terfed tablets and Suspension - a new
non-sedative antihistamine, Depryl tablets - a broad - spectrum
antidepressant, Asthalin Respirator Solution - a bronchodilator for
pressure ventilation in acute asthma. The Company spent Rs 4.22 crores
on R&D and Rs 8.09 crores on modernisation and expansion of plant and


- The new products launched during the year were lomac capsules - a new
antiulcerant, cromal inhaler - the first optimum - dose inhalant
prophylactic for asthma, ciplox eye drops - the total bactericide for
ocular infections, etosid injection - the first injection of
indigenously manufactured etoposide for cancer therapy, proflox tablets
- a key fluoroquinolone antibiotic and vasopril tablets - an ACE
inhibitor for long-term management of hypertension. The research and
development wing of the Company developed during the y ar felodipine -
the latest anti-hypertensive drug, selegilinje - a new bulk drug for
the treatment of Parkinson's disease, cetirizine HCI - an
anti-histamine drug and nimodipine - a cerebral vasodilator. Work on
the anti-AIDS drug AZT reached an advance stage of development. The
research and development wing also developed anthelmintics oxfendazole
and oribendazole, two veterinary products for exports.

- In May, 6,000 equity shares offered at par as rights to pref.
shareholders in prop. 1:1. Only 5,216 shares taken up. Allotment of 5
equity shares pending.


- Some of the new products introduded were Zidovir capsules an
antiretroviral for HIV injection, Cipril tablets for hypertension,
Optipres eyedrops for glaucoma patients, Felogard for hypertension,
Nodine, a non-narcotic analgesic, etc.

- In compliance with the provisions of the Companies Act, 1956, the
Company redeemed its 6,000 preference shares of Rs 100 each as on 30th

- Pref. shares redeemed on 30.9.92, 1,55,395 bonus equity shares issued
in prop. 1:1.


- New products introduced were - Beclate Aquanase - a major advancement
in allergic rhinitis; Cytoplatin - an anticancer agent; Forcan - an
antifungal; Imusporin - an immunosuppressant in organ transplantation;
Kelfer - an iron chelator for thalassaemia; Lanzol - a proton pump
inhibitor; Nuzac - an antidepresant; Odirox - a macrolide antibiotic
and Qinarsol - for chloroquin-resistant malaria.

- Equity shares subdivided 155,39,500. Equity shares allotted shares
issued in prop. 1:5.

- The Company's manufacturing unit at Kurkumbh, which was commissioned
in April. The second phase of expansion of the location was under way
and this was to provide specialised facilities for the manufacture of
new chemical entites.


- Effective 4th July, the Company was forced to declare a lock-out as
some of the workmen at the Vikhroli Unit resorted to indiscipline. The
Company initiated steps to mitigate the impact it could have on

- New products introduced were - Acivir - antivirus herpes, Anlopres -
antivirus herpes, Anlopres - Calcium channel blocker in hypertension
and angina, Anlopres AT - a combination antihypertensive, Budecort 200
- a higher strength corticosterord in bronchial asthma, Budenase AQ - a
corticosteroid protection in allergic rhinitis, cronal - a nast cell
stabiliser in allergic conjunctivitis, cytonid - a antiandrogenic agent
in prostate cancer, Norflox - an antidiarrhoeal in diarrhoea of mixed
origin, optipes S - betaxocol eye drops, profenac - anti-inflammatory
eye drops, Terfed D - a combination antihistamine and decongestant,
Trivedon 20 - used in ischaemic heart disease.

- A new chemical entity, candocuronium iodide - a neuromuscular
blocking agent was manufactured, other new bulk drugs manufactured
include: Acyelovir - antiviral, Amlodipine besylate - antihypertensive
and antianginal, Febantel - veterinary anthelmintic, Flutamide -
antiandrogen, Flutivcasone dipropionate - a corticosteriod, zenprolide
acetate - GMRH analogue.

- 13,43,383 rights equity shares issued (Prem. Rs. 60/-). However, the
Rights issue was underwritten.


- The products launched during the year were Azee (azithromycin
capsules) - a new macrolide antibiotic; Budecort (budesonide rotacaps)
- dry powder inhaled corticosteriod therapy for asthama; Cipril H
(lisionopril + hydrochlorothiazide tablets) - a combination
antihypertensive; Ciplox TZ (ciprofloxacin + tinidazole tablets) - the
combination bactericide for aerobic/anaerobic infections; Entosec
(secnidazole tablets) - single dose therapy for
amoebiasis/trichomoniasis; Fincar (finasterid tablets) - for beign
prostatic hyperphasia; Metolar (metaprolol injection) - beta-blocker
protection for post myocardial infarction & Zoflut (fluticasone
propionate cream) - a new topical corticosteroid.


- The products introduced during the year were; Alerid-D - an
antihistamine and decongestant for cold and congestion, Amlopres L - a
tablet for hypertension, Apuatears - an eye drop, Azee 1000 - a single
dose for STDs, Budecort Respules - neubulised corticosteroid therapy
for asthma, Dilgard XL - a diltiazem, Glumet - tablet for obese
diabetics, Glygard - tablet for abese diabetics, Glygard - tablet for
diabetics, Ipranase AQ (ipratropium nasal spray) - an anticholinergic
therapy for rhinorrhoea, Ocutim (an eye drop) - a glaucoma therapy in
acquafilm formulation, Osteifos 10 - tablet for osteoporosis, Prolyte
Fizz - a rehydration effervescent tablet, Pylokit - an advanced H
pylori kit, Risnia - an a typical antipsychotic, Stavir - an
antiretroviral for AIDS, Synclar 250 - an advanced macrolide
antibiotic, Theoday - a tablet for asthma, Zoflut Lotion - a topical

- The bulk division of the Company had taken up, the development and
manufacture of some new drugs viz., budesonide - antiasthmatic
corticosteroid, carvedilol - alpha/beta blocker, ebastine -
antihistamine, formoterol fumarate - antiasthmatic, meloxicam - for
osteroarthritis and rheumatoid arthritis, moclobemide - antidepressant,
mometasome furoate - antiflammatory corticosteroid, pantorazole sodium
sesquihydrate - antiulcerant, sildenafil citrate - erectile dysfuncion.

- The Company has developed a form-fill-seal equipment for the first
time in India, for the manufacture of sterile formulations. This was
commissioned at Vikhroli factory and is working to its full capacity.
Additional capacities were set up at Kurkumbh for manufacture of
effervescent tablets, soft gel capsules and injectable formulations.
The Company has incurred a capital expenditure of Rs 22.73 crores
during the year.

- The Rs. 3.69 billion Cipla has finalised a marketing joint venture
with Australia-based Genpharm, as part of its strategy to consolidate
its global presence.

- Pharmaceutical major Cipla Ltd grabbed the attention of traders at
the Mumbai Stock Exchange (BSE) on December 26 after a large block of
about 75,000 shares of the company valued at little over Rs 5 crore
changed hands.

- The Rs.369-crore Cipla Ltd has entered into a souring arrangement
with US-based Geneva Pharmaceuticals, a wholly-owned subsidiary of
Swiss multinational Ciba, for a range of generic drugs.


- Pharmaceutical companies, Cipla and Wockhardt, will be seeking
shareholders' approval for a proposed share buyback at their
forthcoming annual general meetings.

- In a notice to shareholders, Cipla has proposed introduction of a new
article, Article 64 A, in the Articles of Association of the company to
enable the company to purchase and re-issue any of its shares. The
existing Article 64 prohibits the company from buying its own shares
and applying any of its funds for the purchase of any shares of the

- The share price of Cipla Ltd, the leading pharmaceutical company
scaled a new peak of Rs 920 on the Mumbai Stock Exchange on Sept 29
following fresh bull charge. The scrip opened at Rs 900 and shot up to
Rs 920 during mid-session and closed at Rs 884 following hectic trading


- Ranbaxy and Cipla, have entered into a strategic partnership to
jointly market a select basket of drugs. The alliance will bring forth
their strengths in the strongly emerging cardiovascular and perennial
anti-infectives market.

- As a first step, the two molecules being jointly launched are
Carvedilol, a new generation anti-hypertensive and Cefpodoxime
Proxetil, an advanced third generation oral cephalosporin.

- The Rs 541-crore Cipla has forged a strategic alliance with the
UK-based Neolab for marketing a range of generic drugs. The alliance,
while improving the Indian company's access to the multi-billion dollar
European market for off-patent drugs, will also see Cipla rake in
royalties on sales of products covered under the deal.

- Cipla's latest tie-up in the international market comes close on the
heels of the company's strategic partnership with the Delhi-based
Ranbaxy Laboratories for a select basket of drugs.

- The Mumbai-based Cipla is working on abbreviated new drug
applications (ANDAs) in collaboration with international generics firms
for a range of products like flutamide (for advanced prostatic cancer)
and felodipine, for hypertension.


- Cipla and Ranbaxy Laboratories have expanded an existing partnership
by adding one more new drug in their co-marketing arrangement.


- Cipla has tied up with the US-based Zenith Goldline and United
Research Labs for marketing Flutamide, an oncology drug, and
Felodipine, a cardiovascular drug, in the US and European markets.

- Domestic pharma giant, Cipla, has despatched its first free
consignment of anti-AIDS drug, Nevirapine, to the Indian Government
for distribution under the public health system.


-Reduces the price of its anti-HIV medicines such as Stavir, Lamivir, Nevimune, Dinex, Indivan, Triomune, Efavir and Duovir

-Revokes interim dividend of Rs 5 per share on face value of Rs 10 per share for FY 2001-02

-Company included in the World Health Organisation's (WHO's) list of HIV-related products

-Chairman and Managing Director YK Hamied was presented with the lifetime contribution award for excellence in the pharmaceutical industry by Union chemicals & fertilisers minister SS Dhindsa

-Resigns from Indian Pharmaceutical Alliance (IPA) over Patents Bill


-Applies its requisiton for Abbreviated New Drug Application (ANDA) with US regulators for a post-menopausal drug

-National Pharmaceutical Pricing Authority (NPPA) issues notices to Cipla along with Ranbaxy for overcharging the products

-Completes research studies on three Anti-HIV Drugs

-Registers Stavudine, Nevirapine, other anti-AIDS products in South Africa


-Signs long-term agreement with Morton Grove Pharmaceuticals Inc (MGP) of Illinois, US, for product launch in the US market

-Avesthagen forges alliance with Cipla

-Cipla has joined a global initiative taken up by the Vatican in collaboration with global generic pharmaceutical manufacturers and the International Federation of Catholic Pharmacies and Academics to float CUMVIVIUM

-Cipla join hands with Pentech Pharma

-Indian pharma major Cipla, a pioneer in supplying cheap generic AIDS drugs in Africa, has patented its three-in-one combination tablet Triomune in South Africa

-Cipla introduces 'Duova' to fight chronic obstructive pulmonary disease

- Launches a new treatment for arthritis in technical collaboration with California-based Cymbiotics Inc.

-Set-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh.
-Cipla introduces new drug for arthritis

-Cipla to sign deal with Akorn Inc for anti-infective drug

-Cipla to produce generic versin of bird-flu drug

-Cipla to join hands with Roche

- Cipla introduces new drug for arthritis


- Cipla receives Scrip Award for Best Company in an Emerging Market
-Safe & steady strategy gives Cipla lead over Ranbaxy
-Cipla sets up subsidiary in Dubai
-Cipla ties up with Ivax for US market
-Cipla receives tentative US FDA approval for AIDS drugs
-Cipla receives Pharma Excellence Award for 'Sustained Growth'


- Cipla unveils anti-malaria global initiative.

-Set-up state-of-the-art facility for manufacture of formulations at Sikkim.
-Award for the Forbes Asia's Best Under A Billion List!
-Ciplas drug included in US anti-AIDS initiative
-Anti-AIDS blitz sees pharma firms locked in ugly battle
-Cipla launches emergency contraception tablet
-Cipla launches estradiol transdermal spray in India
-Cipla launches cut-price zanamivir in India
-Cipla receives International Trade Awards 2006 for outstanding exporter of the year (Pharmaceuticals, Healthcare and Life Sciences category)

-Cipla Ltd has appointed Mr. Pankaj Patel as a Director in casual vacancy with effect from
March 05, 2008.

-Cipla launched Roche's generic version of anti-infection drug


-Cipla wins Erlotinib case against Roche
-Pharmaceuticals Export Promotion Council Awards
-Cipla launches drug to treat Swine flu virus